Aytu BioPharma, Inc.
Simbolis: AYTU
NASDAQ
2.9043
USDRinkos kaina šiandien
-0.9631
P/E santykis
-0.0159
PEG koeficientas
16.17M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Aytu BioPharma, Inc. (AYTU) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 81.66 | 23 | 19.4 | 49.6 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 122.27 | 28.9 | 21.7 | 28.2 | |||||||||||||||||
balance-sheet.row.inventory | 51.6 | 12 | 10.8 | 16.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 4.13 | 0.9 | 0.6 | 1 | |||||||||||||||||
balance-sheet.row.total-current-assets | 293.27 | 72.8 | 59.9 | 105.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 15.7 | 3.9 | 6.3 | 8.7 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 65.8 | |||||||||||||||||
balance-sheet.row.intangible-assets | 235.49 | 59 | 70.6 | 85.5 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 235.49 | 59 | 70.6 | 151.3 | |||||||||||||||||
balance-sheet.row.long-term-investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.tax-assets | 1.38 | 1.4 | 0 | 10.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0.8 | 0.8 | 0.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 254.55 | 63.6 | 77.7 | 160.4 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.account-payables | 53.09 | 13.5 | 11 | 19.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 17.7 | 1.6 | 3.9 | 25.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 55.92 | 14.7 | 14.3 | 2.8 | |||||||||||||||||
Deferred Revenue Non Current | -1.38 | -1.4 | 0 | -11.2 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.38 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 82.35 | 7.1 | 49.5 | 7.4 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 118.45 | 28.1 | 27.1 | 18.7 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.05 | 0.8 | 2.2 | 3.6 | |||||||||||||||||
balance-sheet.row.total-liab | 402.53 | 97.1 | 91.5 | 128.1 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.retained-earnings | -1230.52 | -304.1 | -288.5 | -178.3 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1375.81 | 343.5 | 334.6 | 315.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 547.82 | - | - | - | |||||||||||||||||
Total Investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.total-debt | 73.62 | 16.4 | 18.2 | 28.3 | |||||||||||||||||
balance-sheet.row.net-debt | -8.04 | -6.6 | -1.2 | -21.3 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -18 | -17.1 | -110.2 | -58.3 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 8.72 | 8.8 | 10.3 | 9.2 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 7.31 | 3.3 | 0 | 22.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 3.55 | 6 | 5.2 | 3.6 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 1.71 | -5.8 | -10.9 | 1.7 | |||||||||||||||||
cash-flows.row.account-receivables | -3.79 | -7.2 | 6.5 | 1.5 | |||||||||||||||||
cash-flows.row.inventory | -2.57 | -3.6 | 1.3 | 2.8 | |||||||||||||||||
cash-flows.row.account-payables | 0.19 | 2.4 | -7.7 | -3.2 | |||||||||||||||||
cash-flows.row.other-working-capital | 7.87 | 2.6 | -11 | 0.6 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 2.81 | -0.4 | 76.7 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 6.11 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | -0.4 | -0.1 | -0.1 | 2.4 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.4 | -0.1 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.debt-repayment | -2.39 | -2.3 | -172.5 | -54.9 | |||||||||||||||||
cash-flows.row.common-stock-issued | 3.93 | 15.6 | 11.7 | 45.1 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | -7.22 | -4.4 | 162.3 | 40.2 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -5.68 | 8.9 | 1.5 | 30.3 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0.03 | 3.6 | -30.5 | 1.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 81.66 | 23 | 19.4 | 49.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 81.63 | 19.4 | 49.9 | 48.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 6.11 | -5.1 | -28.8 | -26 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 6.11 | -5.1 | -28.8 | -28.3 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 98.5 | 107.4 | 96.7 | 65.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 36.2 | 40.8 | 44.4 | 36.4 | |||||||||||||||||
income-statement-row.row.gross-profit | 62.29 | 66.6 | 52.3 | 29.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 2.45 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 25.68 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.operating-expenses | 65.31 | 79 | 88.4 | 67.4 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 101.52 | 119.7 | 132.8 | 103.9 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.71 | 4.8 | 4.1 | 23.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -0.31 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -8.26 | -17.1 | 37.2 | -38.2 | |||||||||||||||||
income-statement-row.row.income-before-tax | -17.17 | -17.1 | -110.3 | -58 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 1.25 | -0.1 | -0.1 | 0.3 | |||||||||||||||||
income-statement-row.row.net-income | -16.64 | -17.1 | -110.2 | -58.3 |
Dažnai užduodami klausimai
Kas yra Aytu BioPharma, Inc. (AYTU) bendras turtas?
Aytu BioPharma, Inc. (AYTU) bendras turtas yra 136463000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 45033000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.632.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 1.108.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.169.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.084.
Kas yra Aytu BioPharma, Inc. (AYTU) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -17051000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 16361000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 78961000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 19529000.000.